Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

G. Lupoli Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

V. Nuzzo Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

C. Di Carlo Chair of Gynecology and Obstetrics, School of Medicine, University ‘Federico II’, Naples, Italy

P. Affmito Chair of Gynecology and Obstetrics, School of Medicine, University ‘Federico II’, Naples, Italy

M. Vollery Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

G. Vitale Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

E. Cascone Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

F. Arlotta Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University ‘Federico II’, Naples, Italy

C. Nappi Chair of Gynecology and Obstetrics, School of Medicine, University ‘Federico II’, Naples, Italy

show all

Abstract

High levels of thyroid hormones accelerate bone turnover. The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis. We studied 40 hyperthyroid patients with bone loss, divided into two groups according to menopausal state. Before treatment and after 6 and 12 months, serum thyroid hormones levels, serum osteocalcin level and bone mineral density were evaluated. In all patients we observed an increase in bone mineral density after treatment with alendronate, and a corresponding decrease in serum osteocalcin level.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

Information for

Open access

Opportunities

Help and information

Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature